IL2 and inflammatory bowel disease: Consequently, RhuDex® may be of an advantage in treatment of IBD, because in its presence CTLA-4 can still be engaged by CD86 and sufficient amounts of IL-2 are present in the system, leaving an option for Treg function and maintenance of mucosal immune tolerance.